Trial Outcomes & Findings for Tear Collection in Adult Volunteers (NCT NCT01969162)

NCT ID: NCT01969162

Last Updated: 2014-11-21

Results Overview

Basal (non-stimulated) tear samples were collected from one eye for lipid analysis. 13 different lipids classes were detected in individual tear samples. The concentration of each lipid class is reported in picomoles (pmole).

Recruitment status

COMPLETED

Target enrollment

35 participants

Primary outcome timeframe

Day 1

Results posted on

2014-11-21

Participant Flow

Participant milestones

Participant milestones
Measure
All Participants
Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
Overall Study
STARTED
35
Overall Study
COMPLETED
35
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Tear Collection in Adult Volunteers

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=35 Participants
Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
Age, Continuous
23.0 years
STANDARD_DEVIATION 4.2 • n=5 Participants
Sex: Female, Male
Female
14 Participants
n=5 Participants
Sex: Female, Male
Male
21 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Day 1

Population: A subset of enrolled participants who had non-stimulated (basal) tear samples.

Basal (non-stimulated) tear samples were collected from one eye for lipid analysis. 13 different lipids classes were detected in individual tear samples. The concentration of each lipid class is reported in picomoles (pmole).

Outcome measures

Outcome measures
Measure
All Participants
n=6 Participants
Adult volunteers without ocular disease who have tear samples collected as per protocol. No investigational drug is administered in this study.
Tear Lipid Composition Profile
Cholesterol Ester
39.34 pmole
Standard Deviation 6.78
Tear Lipid Composition Profile
Diacylglycerol
0.76 pmole
Standard Deviation 0.49
Tear Lipid Composition Profile
Free Cholesterol
6.58 pmole
Standard Deviation 3.11
Tear Lipid Composition Profile
Lyso- Phosphatidylcholine
1.48 pmole
Standard Deviation 0.71
Tear Lipid Composition Profile
Lyso- Phosphatidylethanolamine
0.74 pmole
Standard Deviation 0.74
Tear Lipid Composition Profile
Phosphatidylcholine
1.43 pmole
Standard Deviation 0.78
Tear Lipid Composition Profile
Oxygenated Phosphatidylcholine
0.04 pmole
Standard Deviation 0.03
Tear Lipid Composition Profile
Phosphatidylethanolamine
0.19 pmole
Standard Deviation 0.12
Tear Lipid Composition Profile
Phosphatidylserine
0.21 pmole
Standard Deviation 0.16
Tear Lipid Composition Profile
Sphingomyelin
0.75 pmole
Standard Deviation 0.34
Tear Lipid Composition Profile
Triacylglycerol
2.17 pmole
Standard Deviation 1.01
Tear Lipid Composition Profile
Wax Ester
45.14 pmole
Standard Deviation 5.24
Tear Lipid Composition Profile
(O-acyl)-omega-hydroxy fatty acid
1.18 pmole
Standard Deviation 0.60

Adverse Events

All Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Therapeutic Area Head,

Allergan, Inc

Phone: 714-246-4500

Results disclosure agreements

  • Principal investigator is a sponsor employee A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is no more than 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
  • Publication restrictions are in place

Restriction type: OTHER